Neurocrine Biosciences Reports Rapid TD Symptom Relief in Intellectually Disabled Patients

Event summary

  • Neurocrine Biosciences presented data showing 89% of intellectually disabled TD patients improved within 4 weeks of INGREZZA treatment.
  • Clinicians reported functional improvements in 96% of patients with impaired function after INGREZZA treatment.
  • Study included 30 patients with intellectual/developmental disabilities, mean age 47.3, primarily with schizophrenia (70%) or mood disorders (17%).
  • Findings presented at American Academy of Developmental Medicine and Dentistry's 24th Annual Education Conference.
  • INGREZZA is a VMAT2 inhibitor approved for TD and Huntington's disease chorea.

The big picture

Neurocrine's data highlights the critical need for TD treatments in intellectually disabled patients, a population often overlooked in clinical research. The rapid functional improvements observed suggest INGREZZA could become a standard treatment option, potentially expanding its market beyond current indications. This positions Neurocrine as a leader in addressing movement disorders in complex patient populations.

What we're watching

Market Expansion
Whether Neurocrine can leverage these findings to expand INGREZZA's use in under-served patient populations.
Regulatory Strategy
How the company will position these data for potential label expansions or new indications.
Competitive Positioning
The pace at which competitors develop similar VMAT2 inhibitors targeting TD in special populations.